Lentigen and Expression Therapeutics sign collaboration agreement
Lentigen and Expression Therapeutics will develop two types of treatments for hemophilia: a novel chimeric factor VIII protein for direct injection and a cell therapy that may permanently
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.